We are live on ! Find out more

First Trust Nasdaq Pharmaceuticals ETF

FTXH

Market cap $1.19B

44.15 USD

-0.41

0.92%

At close Updated Nov 12, 4:00 PM EST

1 day

-0.92%

5 days

3.42%

1 month

7.03%

3 months

10.43%

6 months

28.64%

Year to date

33.3%

1 year

40.2%

5 years

63.52%

10 years

127.93%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks

Many of the hot new drug candidates in the U.S. were developed Chinese companies.

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks

Zacks Investment Research

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the First Trust NASDAQ Pharmaceuticals ETF (FTXH), a passively managed exchange traded fund launched on September 20, 2016.

Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)?

Zacks Investment Research

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a passively managed exchange traded fund launched on September 20, 2016.

Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)?

Trump to announce discount drug pricing expansion, White House official says

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday, a White House official said.

Trump to announce discount drug pricing expansion, White House official says

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Medical Technology Stocks: Innovation Endures As Valuations Reset

Could pressure to make money faster kill the next lifesaving pill?

When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.

Could pressure to make money faster kill the next lifesaving pill?

Trump's 100% Pharma Tariffs Will Have A Limited Effect On The Sector

On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. The specifics remain unclear, but the levy is expected to be relatively narrow in scope, since many exemptions have already been negotiated.

Trump's 100% Pharma Tariffs Will Have A Limited Effect On The Sector

Europe's Last Chance To Revive Its Pharmaceutical Innovation Power

Europe's pharmaceutical industry needs to make sure it doesn't become yesterday's news. Its biopharmaceutical innovation capacity has been gradually declining for decades, and the rapid ascent of China and President Trump's policies risk accelerating that decay.

Europe's Last Chance To Revive Its Pharmaceutical Innovation Power

See News Rankings

Price charts implemented using Lightweight Charts™